Duke Royalty agrees €10m royalty with Fairmed
Duke Royalty has entered into a €10m royalty financing agreement with Fairmed Healthcare AG a Swiss based provider of generic prescription medicines, over-the-counter pharmaceuticals, dermocosmetics and dietary supplements across the EU. Fairmed is majority owned by Strides Pharma Global Pte Ltd which is in turn a wholly-owned step-down subsidiary of Bombay-listed Strides Pharma Science Limited. The €10m royalty is a 30-year senior secured financing, with monthly payments commencing immediately in July 2021 on Duke’s typical investment terms.
VIDEO: DUKE ROYALTY INVESTORS OVERVIEW
DUKE ROYALTY INVESTOR VIDEOS